Among CKD patients without prior cardiovascular disease, beta-blocker use was associated with increased risks of all-cause mortality (HR 2.09; 95% CI 1.96-2.24) and MACE (HR 1.33; 95% CI 1.26-1.41).
Cohort (n=26,161)
Sí
Does beta-blocker use reduce all-cause mortality and MACE in CKD patients without established CVD?
In patients with chronic kidney disease but no established cardiovascular disease, beta-blocker use is associated with an increased risk of mortality and cardiovascular events, highlighting the need for caution and further investigation into their safety for primary prevention in this population.
Hazard Ratio: 2.09 (95% CI 1.96–2.24)
Abstract Background Chronic kidney disease (CKD) is strongly linked to cardiovascular disease (CVD) risk. Although beta-blockers (BBs) are widely used for CVD prevention, their effectiveness and safety in CKD patients without established CVD remain uncertain. Methods We conducted a nationwide cohort study using Korean health insurance data. CKD patients without established CVD between 2012 and 2015 were identified based on an estimated glomerular filtration rate (eGFR) 60 mL/min/1.73m2 on at least two occasions. BB users were defined as those prescribed BBs for ≥ 6 months. Primary outcomes were all-cause mortality and 4-point major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, stroke, and hospitalization for heart failure. A 1:2 propensity score matching was performed, and Cox proportional hazards models were applied. Subgroup analyses were also conducted by eGFR category and BB agents. Results After matching, 9,067 BB users and 17,094 non-users were included. BB use was associated with increased risks of all-cause mortality (hazard ratio HR, 2.09; 95% confidence interval CI, 1.96–2.24) and MACE (HR, 1.33; 95% CI, 1.26–1.41). The increased risks were consistent across individual outcomes, including CV death (HR 2.07; 95% CI, 1.66–2.57), myocardial infarction (HR 1.29; 95% CI, 1.13–1.46), stroke (HR 1.21; 95% CI 1.13–1.31), and heart failure hospitalization (HR 1.58; 95% CI, 1.44–1.72). Subgroup analysis showed greater mortality risk at lower eGFR levels and a higher risk of adverse events with carvedilol compared with other BBs. Conclusions Among CKD patients without established CVD, BB use was associated with increased mortality and cardiovascular risk. Further studies are needed to clarify whether these associations reflect treatment effects or underlying patient risk.
Han et al. (Thu,) conducted a cohort in Chronic kidney disease without established cardiovascular disease (n=26,161). Beta-blockers vs. Non-users was evaluated on All-cause mortality and 4-point major adverse cardiovascular events (MACE) (HR 2.09, 95% CI 1.96-2.24). Among CKD patients without prior cardiovascular disease, beta-blocker use was associated with increased risks of all-cause mortality (HR 2.09; 95% CI 1.96-2.24) and MACE (HR 1.33; 95% CI 1.26-1.41).